Citations

Clear

167 citation(s) found for "Grogan, M".

Outcomes of Patients With Familial Transthyretin Amyloidosis After Liver Transplantation
Banerjee, Dipti, Roeker, Lindsey E. , Grogan, Martha , Poterucha, John J., Zeldenrust, Steve R., Edwards, Brooks S., Daly, Richard C. , Klarich, Kyle W. , Poterucha, John, Zeldenrust, Steve, Edwards, Brooks, Daly, Richard , Swiecicki, Paul Loren , Heimbach, Julie K. , Zeldenrust, Steven R., Gertz, Morie A. , Dispenzieri, Angela , Roeker, Lindsey

Mayo Clinic

Progress in Transplantation | August 3, 2017 | Volume: 27 | Issue: 3 | Pages: 246-250

10.1177/1526924817715463 | PMID 29187090 Get It

Background: Familial transthyretin amyloidosis is a disease caused by misfolded transthyretin aggregates that can impair multiple organ systems. Liver transplantation is the first-line treatment for familial transthyretin amyloidosis. Research Question: Our objective is to study outcomes and survival among patients with familial transthyretin amyloidosis after transplantation. Design: All patients undergoing orthotopic liver transplant for familial transthyretin amyloidosis at Mayo Clinic between 1997 and 2012 were reviewed. Baseline clinical characteristics, organs transplanted, and posttransplant clinical course were assessed. Results: Of the 40 patients, 7 patients had the V30M mutation and 33 had other mutations. Nineteen patients received liver only, 19 liver and heart, and 2 combined liver, heart, and kidney transplants. The 5-year overall survival was 85% for those receiving multiple organ transplant and 52% for those receiving liver transplant only ( P = .057). There was no difference in overall survival based on mutation (V30M vs other mutations), but survival was confounded by varied disease involvement and organs transplanted. Those who had early death (≤24 months from liver transplant) had a higher incidence of baseline peripheral neuropathy, autonomic neuropathy, lower modified BMI, and higher alkaline phosphatase. Discussion: Outcomes of orthotopic liver transplant in familial transthyretin amyloidosis are variable due to heterogeneity in mutations and patient status at the time of transplant. Familial transthyretin amyloidosis can progress, despite liver transplantation. Patients receiving combined liver, heart/kidney transplant demonstrated improved survival compared to liver transplant alone.
48 Utilisation of cardiac implantable electronic device therapy in patientswith attr-wild type amyloidosis with concurrent cardiac involvement
Chahal, C. Anwar A. , Padmanabhan, Deepak , Tandon, Nidhi , Grogan, Martha , Brady, Peter A. , Lin, Grace , Somers, Virend K. , Dispenzieri, Angela , Chahal, Choudhary Anwar A

Mayo Clinic

Heart | July 20, 2017 | Volume: 103 | Issue: Suppl 5 | Pages: A38.1-A38

10.1136/heartjnl-2017-311726.47 Get It

Introduction The role of cardiac implantable electronic device (CIED) therapy in patients with ATTR-wt (senile) amyloid is not very well defined. It is unknown whether there is mortality benefit or harm with the implantation of CIEDs. Methods We performed a retrospective analysis of a prospectively collected registry of patients with biopsy proven ATTR-wt amyloid with cardiac involvement. These patients were followed up at Mayo Clinic, Rochester, Minnesota between Jan 1, 1985 to Sep 30, 2015. The follow-up of these patients was done via personal communication (written or verbal) and entered into the database. During analysis these patients were subdivided on the basis of the presence or absence of a CIED, cardiac involvement or not, and all-cause mortality analysed. The implantation of a CIED was analysed as a time-dependent covariate in the survival of these patients and Kaplan-Meier (K-M) survival plots created. Comparison between groups with CIED and those without CIED was made. In addition, CIEDs were subdivided into permanent pacemakers (PPM), defibrillators (ICDs) and cardiac resynchronization devices (CRT-P/D). Mortality among the patients with each device subtype was estimated and compared to overall mortality. Results 409 patients with ATTR-wt and cardiac involvement were reviewed with CIEDs implanted in 101 (25%) patients. The median follow-up (25th, 75th centile) was 2.4 (1.1, 4.3) years. Utilisation of ICDs in this population was higher than the general community in Olmsted county. There was no association in the overall survival or evidence of harm with CIED utilisation in patients with ATTR amyloidosis and cardiac involvement. Conclusions CIEDs utilisation remains high in ATTR-wt with cardiac involvement. Due diligence is needed in selecting the optimal patient for benefit prior to the implantation of CIEDs in this cohort. Further research is required to pool multi-centre amyloid registry data and determine if there is mortality benefit.
Recommendations from the Amyloidosis Research Consortium Educational Roundtable at the American College of Cardiology Annual Meeting, 1 April 2016
Maurer, Mathew S. , Lousada, Isabelle , Hanna, Mazen , Ruberg, Frederick L. , Mohty, Dania , Liedtke, Michaela , Paulson, Ingrid , Vest, John, Grogan, Martha , Maurer, Mathew S , Dispenzieri, Angela , Vest, John

Mayo Clinic

Amyloid | April 22, 2017 | Volume: 24 | Issue: sup1 | Pages: 165-166

10.1080/13506129.2017.1286582 | PMID 28434366 Get It

Feasibility study of cardiac magnetic resonance elastography in cardiac amyloidosis
Chang, Ian C , Arani, Arvin , Arunachalam, Shivaram P. , Grogan, Martha , Araoz, Philip A. , Chang, Ian C Y, Poigai Arunachalam, Shivaram, Dispenzieri, Angela , Arunachalam, S P , Arani, Arvin

Mayo Clinic

Amyloid | April 22, 2017 | Volume: 24 | Issue: sup1 | Pages: 161-161

10.1080/13506129.2017.1278689 | PMID 28434361 Get It

Complex p.T88N/W130R mutation in the lysozyme gene leading to hereditary lysozyme amyloidosis with biopsy-proven cardiac involvement
Sperry, Brett W. , Ikram, Asad , Grogan, Martha , Theis, Jason D. , Highsmith, W. Edward, Maleszewski, Joseph J. , Hanna, Mazen , Sperry, Brett W , Dispenzieri, Angela , Leung, Nelson

Mayo Clinic

Amyloid | March 23, 2017 | Volume: 24 | Issue: 1 | Pages: 60-61

10.1080/13506129.2016.1269738 | PMID 28330375 Get It

Cardiac MR elastography for quantitative assessment of elevated myocardial stiffness in cardiac amyloidosis
Arani, Arvin , Arunachalam, Shivaram P. , Chang, Ian C , Baffour, Francis , Rossman, Phillip J. , Glaser, Kevin J. , Trzasko, Joshua D. , McGee, Kiaran P. , Grogan, Martha , Dispenzieri, Angela , Araoz, Philip A. , Chang, Ian C Y, Manduca, Armando , Ehman, Richard L. , Dispenzieri, Angela , Arunachalam, S P , Arani, Arvin , Baffour, Francis I

Mayo Clinic

Journal of Magnetic Resonance Imaging | February 25, 2017 | Volume: 46 | Issue: 5 | Pages: 1361-1367

10.1002/jmri.25678 | PMID 28236336 Get It

PurposeTo evaluate if cardiac magnetic resonance elastography (MRE) can measure increased stiffness in patients with cardiac amyloidosis. Myocardial tissue stiffness plays an important role in cardiac function. A noninvasive quantitative imaging technique capable of measuring myocardial stiffness could aid in disease diagnosis, therapy monitoring, and disease prognostic strategies. We recently developed a high‐frequency cardiac MRE technique capable of making noninvasive stiffness measurements.Materials and MethodsIn all, 16 volunteers and 22 patients with cardiac amyloidosis were enrolled in this study after Institutional Review Board approval and obtaining formal written consent. All subjects were imaged head‐first in the supine position in a 1.5T closed‐bore MR imager. 3D MRE was performed using 5 mm isotropic resolution oblique short‐axis slices and a vibration frequency of 140 Hz to obtain global quantitativein vivoleft ventricular stiffness measurements. The median stiffness was compared between the two cohorts. An octahedral shear strain signal‐to‐noise ratio (OSS‐SNR) threshold of 1.17 was used to exclude exams with insufficient motion amplitude.ResultsFive volunteers and six patients had to be excluded from the study because they fell below the 1.17 OSS‐SNR threshold. The myocardial stiffness of cardiac amyloid patients (median: 11.4 kPa, min: 9.2, max: 15.7) was significantly higher (P = 0.0008) than normal controls (median: 8.2 kPa, min: 7.2, max: 11.8).ConclusionThis study demonstrates the feasibility of 3D high‐frequency cardiac MRE as a contrast‐agent‐free diagnostic imaging technique for cardiac amyloidosis.Level of Evidence:2Technical Efficacy:Stage 2J. Magn. Reson. Imaging 2017;46:1361–1367.
Discrepancies in Clinical Laboratory Testing of Eligibility for Trastuzumab Therapy: Apparent Immunohistochemical False-Positives Do Not Get the Message
Tubbs, Raymond R., Pettay, James, Roche, Patrick C. , Stoler, Mark H. , Jenkins, Robert B. , Grogan, Thomas M.

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 19 | Issue: 10 | Pages: 2714-2721

10.1200/jco.2001.19.10.2714 | PMID 11352964 Get It

BACKGROUND: Several studies have reported what seem to be false-positive results using the Food and Drug Administration (FDA)–approved HercepTest (Dako Corp, Carpinteria, CA) to profile Her-2/neu amplification and overproduction in breast carcinoma. False-positive status has been based on comparisons with gene copy enumeration by fluorescence in situ hybridization (FISH) and with comparisons to immunohistochemistry (IMH) results using a monoclonal antibody. However, simple overexpression by tumor cells that have normal gene copy has not been evaluated by profiling mRNA expression, ie, such cases could simply represent true-positive, transcriptionally upregulated overexpression. MATERIALS AND METHODS: Four hundred infiltrating ductal carcinomas of breast were evaluated by IMH using monoclonal (CB11; Ventana Medical Systems, Inc, Tucson, AZ) and polyclonal (HercepTest; Dako) antibodies after antigen retrieval (AR). A polyclonal antibody sans AR (PCA/SAR) was also used. All IMH stains were evaluated and scored according to the guidelines for the FDA-approved HercepTest. A total of 145 of 400 carcinomas were subsequently evaluated by direct and digoxigenin-labeled (Dig) FISH, and 144 of 400 were evaluated by detection of mRNA overexpression via autoradiographic RNA:RNA in situ hybridization. RESULTS: Overall HercepTest/CB11 IMH discordance was 12%. Expression of mRNA was highly concordant with FISH and DigFISH amplification and with CB11 and PCA/SAR immunohistology. IMH false-positive cases (no Her-2/neu gene amplification) occurred with both HercepTest (23%) and CB11 (17%), and the majority of false-positive results (34 of 44) were scored as 2+. All 2+ false-positive cases were mRNA-negative. Combined results of HercepTest and CB11 showed that 79% (38 of 48) of 3+ cases were Her-2/neu gene amplified, but only 17% (seven of 41) of 2+ cases had increased gene copy. CONCLUSION: Discordant HercepTest/FISH results, and to a lesser extent discordance with CB11 IMH, are most commonly false-positive results with a score of 2+. The 2+ score as defined in the guidelines for the FDA-approved HercepTest should not be used as a criterion for trastuzumab therapy unless confirmed by FISH. Determination of Her-2 gene copy number by FISH may be a more accurate and reliable method for selecting patients eligible for trastuzumab therapy.
Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death
Muchtar, Eli , Gertz, Morie A. , Kumar, Shaji , Lacy, Martha Q. , Dingli, David , Grogan, Martha , Hayman, Suzanne R. , Kapoor, Prashant , Fonder, Amie , Hobbs, Miriam, Hwa, Yi L. , Warsame, Rahma , Kourelis, Taxiarchis , Russell, Stephen J. , Lust, John A., Lin, Yi , Zeldenrust, Steven R., Kyle, Robert A. , Buadi, Francis K. , Leung, Nelson , Gonsalves, Wilson I. , Go, Ronald S. , Rajkumar, S. Vincent , Dispenzieri, Angela , Gertz, Morie A , Muchtar, E , Russell, Stephen J , Dingli, David , Lin, Yi

Mayo Clinic

Blood | January 26, 2017 | Volume: 129 | Issue: 15 | Pages: 2111-2119

10.1182/blood-2016-11-751628 | PMID 28126928 Get It

Key Points Significant improvement in outcome is a reality for newly diagnosed AL amyloidosis in the past decade. Six-month mortality among transplant ineligible patients has declined since 2005.
Ventricular‐Arterial Function and Coupling in the Adult Fontan Circulation
Saiki, Hirofumi , Eidem, Benjamin W., Ohtani, Tomohito , Grogan, Martha , Redfield, Margaret M. , Grogan, Martha A

Mayo Clinic

Journal of the American Heart Association | September 23, 2016 | Volume: 5 | Issue: 9 | Pages: No page available

10.1161/jaha.116.003887 | PMID 27663413 Get It

Background In adult Fontan patients, ventricular or arterial dysfunction may impact homeostasis of the Fontan circulation and predispose to heart failure. We sought to characterize ventricular‐arterial ( VA ) properties in adult Fontan patients. Methods and Results Adult Fontan patients (n=170), including those with right ( SRV , n=57) and left ( SLV , n=113) dominant ventricular morphology, were compared to age, sex, and body size matched controls (n=170). Arterial function, load‐insensitive measures of contractility, VA coupling, diastolic function, and ventricular efficiency were assessed. Compared to controls, Fontan patients had similar arterial (Ea), but lower end‐systolic ventricular (Ees), elastance, preload recruitable stroke work and peak power index, impaired VA coupling, eccentric remodeling, reduced ventricular efficiency and increased diastolic stiffness ( P <0.05 for all). Ventricular efficiency declined steeply with higher heart rate in Fontan, but not control, patients. Among Fontan patients (n=123) and controls (n=162) with preserved cardiac index ( CI ; ≥2.5 L/min per m 2 ), Fontan patients had worse contractility than controls, but CI was preserved owing to relative tachycardia, lower afterload, and eccentric remodeling. However, 25% of Fontan patients had reduced CI and were distinguished from those with preserved CI by less‐eccentric remodeling and worse diastolic function, rather than more‐impaired contractility. Conclusions Adult Fontan patients have contractile and diastolic dysfunction with normal afterload, impaired VA coupling, and reduced ventricular efficiency with heightened sensitivity to heart rate. Maintenance of CI is dependent on lower afterload, eccentric remodeling, and relative preservation of diastolic function. These data contribute to our understanding of circulatory physiology in adult Fontan patients.